New combo therapy tested for hard-to-treat breast cancer
NCT ID NCT03742245
First seen Dec 17, 2025 · Last updated May 24, 2026 · Updated 24 times
Summary
This early-stage trial tests the safety of combining two drugs, olaparib and vorinostat, in people with advanced breast cancer that has returned or spread. The study includes 28 adults whose cancer is not HER2-positive. The goal is to find the best dose and check for side effects, not to cure the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Houston Methodist Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.